{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:02:03Z","timestamp":1781103723856,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dasatinib, which is used to treat treating chronic myeloid leukemia, induces increases in blood lymphocytes during the treatment. In addition, neutrophil\u2013lymphocyte count ratio (NLR) is associated with the related to development of chronic kidney disease (CKD). However, it has not been reported whether development of CKD during long-term dasatinib treatment is related to lymphocyte count or NLR. This study aimed to reveal the relationship between CKD and lymphocyte count or NLR during long-term dasatinib treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective study was conducted in patients treated with dasatinib for 6\u00a0months or longer. Risk factors for CKD development were explored using multivariate analysis. Changes in maximal lymphocyte count and NLR over time were examined separately.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 33 patients in CKD group (<jats:italic>n<\/jats:italic>\u2009=\u20098) and No CKD group (<jats:italic>n<\/jats:italic>\u2009=\u200925) who received dasatinib were enrolled. In univariate analysis, significant differences between the groups were observed in maximal lymphocyte count, lymphocytosis, age, and estimated glomerular filtration rate at baseline. As the factor independently associated with the development of CKD, maximal lymphocyte count (odds ratio 0.999, 95% confidence interval: 0.999\u20131.000, <jats:italic>p<\/jats:italic>\u2009=\u20090.033) was identified. In this analysis, age had borderline significance (odds ratio 1.073, 95% CI: 0.999\u20131.153, <jats:italic>p<\/jats:italic>\u2009=\u20090.054)]. After 6\u00a0months of dasatinib therapy, lymphocyte count was significantly lower in CKD group [median (range), 2184 (878\u20123444)\/\u03bcL] than in the No CKD group [3501 (966\u20127888)\/\u03bcL] (<jats:italic>p<\/jats:italic>\u2009=\u20090.020). However, no significant difference in lymphocyte count was observed between the groups at the last follow-up. During the study period, the median NLR in the No CKD group fluctuated between 1.11 and 1.42, and median NLR in CKD group was increased from 1.13 to 2.24 between after 6\u00a0months of dasatinib therapy and the last follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The development of CKD during dasatinib therapy was associated with lower maximal lymphocyte counts. In contrast, the higher levels of lymphocytes induced during dasatinib treatment may prevent CKD progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-022-00270-x","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T17:02:40Z","timestamp":1674493360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is higher lymphocyte count a potential strategy for preventing chronic kidney disease in patients receiving long-term dasatinib treatment?"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9758-8004","authenticated-orcid":false,"given":"Hirokazu","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"270_CR1","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370. https:\/\/doi.org\/10.1056\/NEJMoa1002315.","journal-title":"N Engl J Med."},{"key":"270_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341. https:\/\/doi.org\/10.1056\/NEJMoa055229.","journal-title":"N Engl J Med."},{"key":"270_CR3","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186-93. https:\/\/doi.org\/10.1016\/S2352-3026(15)00048-4.","journal-title":"Lancet Haematol."},{"key":"270_CR4","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1002\/cncr.29587","volume":"121","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Lahoti A, O\u2019Brien S, Nogueras-Gonz\u00e1lez GM, Burger J, Ferrajoli A, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015;121:3894\u2013904. https:\/\/doi.org\/10.1002\/cncr.29587.","journal-title":"Cancer."},{"key":"270_CR5","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1053\/j.ajkd.2013.01.022","volume":"61","author":"E Wallace","year":"2013","unstructured":"Wallace E, Lyndon W, Chumley P, Jaimes EA, Fatima H. Dasatinib-induced nephrotic-range proteinuria. Am J Kidney Dis. 2013;61:1026\u201331. https:\/\/doi.org\/10.1053\/j.ajkd.2013.01.022.","journal-title":"Am J Kidney Dis."},{"key":"270_CR6","doi-asserted-by":"publisher","unstructured":"Koinuma K, Sakairi T, Watanabe Y, IIzuka A, Watanabe M, Hamatani H, et al. A case of long-term dasatinib-induced proteinuria and glomerular injury. CEN Case Rep. 2020;9:359\u201264. https:\/\/doi.org\/10.1007\/s13730-020-00484-8.","DOI":"10.1007\/s13730-020-00484-8"},{"key":"270_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11255-018-1994-7","volume":"51","author":"O Altunoren","year":"2019","unstructured":"Altunoren O, Akkus G, Sezal DT, Ciftcioglu M, Guzel FB, Isiktas S, et al. Does neutrophyl to lymphocyte ratio really predict chronic kidney disease progression? Int Urol Nephrol. 2019;51:129\u201337. https:\/\/doi.org\/10.1007\/s11255-018-1994-7.","journal-title":"Int Urol Nephrol."},{"key":"270_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/leu.2012.348","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia. 2013;27:914\u201324. https:\/\/doi.org\/10.1038\/leu.2012.348.","journal-title":"Leukemia."},{"key":"270_CR9","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1097\/MJT.0000000000001289","volume":"29","author":"H Nakayama","year":"2022","unstructured":"Nakayama H, Iizuka H, Kato T, Usuki K. Dasatinib-Associated Creatine Kinase Level Elevation. Am J Ther. 2022;29:e690-4. https:\/\/doi.org\/10.1097\/MJT.0000000000001289.","journal-title":"Am J Ther."},{"key":"270_CR10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis."},{"key":"270_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood. 1984;63:789\u201399.","journal-title":"Blood"},{"key":"270_CR12","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398\u2013405. https:\/\/doi.org\/10.1038\/leu.2009.46.","journal-title":"Leukemia."},{"key":"270_CR13","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/cncr.29933","volume":"122","author":"CA Schiffer","year":"2016","unstructured":"Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, et al. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. 2016;122:1398\u2013407. https:\/\/doi.org\/10.1002\/cncr.29933.","journal-title":"Cancer"},{"key":"270_CR14","unstructured":"Common Terminology Criteria for Adverse Events version 4.03: (https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.) cited August 1st, 2021."},{"key":"270_CR15","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00277-019-03690-2","volume":"98","author":"X Ren","year":"2019","unstructured":"Ren X, Qin Y, Huang X, Zuo L, Jiang Q. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors. Ann Hematol. 2019;98:1627\u201340. https:\/\/doi.org\/10.1007\/s00277-019-03690-2.","journal-title":"Ann Hematol."},{"issue":"1","key":"270_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/0886022X.2019.1595645","volume":"41","author":"R Yoshitomi","year":"2019","unstructured":"Yoshitomi R, Nakayama M, Sakoh T, Fukui A, Katafuchi E, Seki M, et al. High neutrophil\/lymphocyte ratio is associated with poor renal outcomes in Japanese patients with chronic kidney disease. Ren Fail. 2019;41(1):238\u201343. https:\/\/doi.org\/10.1080\/0886022X.2019.1595645.","journal-title":"Ren Fail"},{"key":"270_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cncr.32504","volume":"126","author":"K Naqvi","year":"2020","unstructured":"Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;126:67\u201375. https:\/\/doi.org\/10.1002\/cncr.32504.","journal-title":"Cancer"},{"key":"270_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00277-018-3258-0","volume":"97","author":"M Breccia","year":"2018","unstructured":"Breccia M, Palandri F, Luciano L, Benevolo G, Bonifacio M, Caocci G, et al. Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. Ann Hematol. 2018;97:745\u201354. https:\/\/doi.org\/10.1007\/s00277-018-3258-0.","journal-title":"Ann Hematol"},{"key":"270_CR19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.clml.2017.02.023","volume":"17","author":"H Itamura","year":"2017","unstructured":"Itamura H, Kubota Y, Shindo T, Ando T, Kojima K, Kimura S. Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg. Clin Lymphoma Myeloma Leuk. 2017;17:370\u20134. https:\/\/doi.org\/10.1016\/j.clml.2017.02.023.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"270_CR20","first-page":"428","volume":"75","author":"AHG Muller-Hansma","year":"2017","unstructured":"Muller-Hansma AHG, van der Lugt J, Zwaan CM. Nephrotic syndrome under treatment with dasatinib: be aware of a possible adverse drug reaction. Neth J Med. 2017;75:428\u201331.","journal-title":"Neth J Med"},{"key":"270_CR21","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00277-018-3375-9","volume":"97","author":"M Molica","year":"2018","unstructured":"Molica M, Scalzulli E, Colafigli G, Fegatelli DA, Massaro F, Latagliata R, Fo\u00e0 R, Breccia M. Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. Ann Hematol. 2018;97:1803\u20138. https:\/\/doi.org\/10.1007\/s00277-018-3375-9.","journal-title":"Ann Hematol"},{"key":"270_CR22","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdq715","volume":"22","author":"MS Marcolino","year":"2011","unstructured":"Marcolino MS, Boersma E, Clementino NCD, Macedo AV, Marx-Neto AD, Silva MHCR, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol. 2011;22:2073\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdq715.","journal-title":"Ann Oncol"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-022-00270-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-022-00270-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-022-00270-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T17:04:54Z","timestamp":1674493494000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-022-00270-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1186\/s40780-022-00270-x","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"4 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of the present study was approved by the Ethics Committee of NTT Medical Center Tokyo (approval number 19\u2009\u2212\u2009380) prior to study commencement.The requirement of written informed consent from patients was waived due to the retrospective nature of the present study. Data used were obtained from routine medical care. The study was conducted with full consideration for protection of patients\u2019 personal information, according to privacy policy guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HN and HI declare no conflicts of interest.TK has served on speakers\u2019 bureaus for AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Elmed Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd and Yakult Honsha Co., Ltd.KU has received research funding from and served on speakers bureaus for the following incorporations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}